#HepatitisB Archives

Expert Interview with Dr. Jiajie Liao: Optimizing Cost-Effective Strategies for Hepatitis B Treatment

By Mourabit Halima 2025.01.06

Recently, the American Association for the Study of Liver Diseases (AASLD 2024) was held in San Diego, USA. The prestigious event brought together leading experts and scholars in the field…

Expert Interview with Dr. Jun Li: New Insights into Hepatitis B-Related ACLF Research

By Lisa Cui 2025.01.02

Acute-on-Chronic Liver Failure (ACLF) is one of the most severe and life-threatening liver diseases in China and the Asia-Pacific region. This complex condition arises from multiple factors, with host genetic…

AASLD Exclusive Interview with Dr. Grace Lai-Hung Wong: Quantitative HBsAg – A New Perspective in Advancing Hepatitis B Management and Functional Cure

By Peng Longmei 2024.12.27

With significant progress in hepatitis B treatment, particularly in the pursuit of a functional cure, the quantification of hepatitis B surface antigen (HBsAg) has emerged as a critical factor in…

AASLD 2024丨Dr. Hui Wang’s Team: Serum HBV RNA and HBcrAg as Predictors of Low-Level Viremia in CHB Patients Treated with Nucleos(t)ide Analogs

By Mourabit Halima 2024.12.23

At the 2024 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Dr. Hui Wang’s team from the Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao…

AASLD 2024丨Dr. Jie Li and Dr. Li Zhu: PRO-C3 and GP73 Combined Non-Invasive Fibrosis Score Wins Poster of Distinction

By Mourabit Halima 2024.12.10

During the 2024 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), a research team led by Dr. Jie Li from Nanjing Drum Tower Hospital, Nanjing…

AASLD Featured New Voices | Terry Yip and Jimmy Lai Explore the New Progress of Liver Disease

By Mourabit Halima 2024.12.05

Editor's note: At the recent AASLD 2024, the annual meeting of the American Association for the Study of Liver Diseases, top experts from the global liver disease field gathered to…

Dr.Hong You and Dr.Wei Chen’s Team Proliferative T Cell Subpopulations in the Liver Promote Fibrosis Reversal in CHB Patients After Antiviral Therapy

By Qingyuan Liu 2024.12.03

Chronic Hepatitis B (CHB) is a prevalent chronic inflammatory liver disease in China, often resulting in sustained hepatic parenchymal damage, liver fibrosis, and adverse outcomes such as cirrhosis, liver failure,…

AASLD 2024 | Nadege Pelletier: Exploring new hope for innovative immunotherapy for chronic hepatitis B

By Mourabit Halima 2024.12.03

Editor's note: Chronic hepatitis B (CHB) is a major public health problem worldwide. Although traditional antiviral drugs can inhibit viral replication to some extent, they are still inadequate in achieving…

AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations

By Lisa Cui 2024.12.02

The 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) took place in San Diego, USA, from November 15 to 19, 2024. Six research projects…

AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations

By El Bachir MOURABIT 2024.12.02

Hepatocellular carcinoma (HCC) imposes a significant health and economic burden on patients. Screening, recognized as an effective strategy to improve early diagnosis rates in high-risk populations, has garnered broad acknowledgment…